The acquisition brings MLM’s laboratory network and scientific service capabilities into Labcorp’s global infrastructure, expanding the company’s wholly owned laboratory footprint
The findings are particularly significant because the trial population had a high burden of severe obesity
The company said RZ-520 has been designed to maintain drug exposure within the lungs while limiting systemic distribution
The pivotal cardiovascular outcomes trial did not meet its primary endpoint
The company expects to report interim data from MASH patients in 2027
Suven expects the last patient last visit (LPLV) by the end of December 2026
Both were dual primary endpoints of the trial, and the differences were statistically significant, AbbVie said
The study met its primary endpoint
The findings from the SANOVO trial in China strengthen the case for Tagrisso as a backbone treatment for EGFR-mutated non-small cell lung cancer
GSK plans to begin a Phase III efficacy trial in September 2026
The results point to potential benefits beyond relapse control
The acquisition is expected to strengthen Inceptua's Pharmacy Model capabilities in North America
The results build on statistically superior outcomes reported at Week 36, when the combination outperformed Taltz alone on key disease and metabolic measures
The Australian biotech player is evaluating the therapy in patients with relapsed or refractory kappa-restricted multiple myeloma
EVIDENCES-X trial met its primary endpoint, with a 26.5% treatment difference in MASH resolution without worsening of fibrosis
The treatment also enabled longer dosing intervals for many patients
The trial’s two co-primary endpoints assessed histologic remission and the frequency and severity of dysphagia
The study’s co-primary endpoints were clinical remission, defined as a Crohn’s Disease Activity Index (CDAI) score below 150
Subscribe To Our Newsletter & Stay Updated
